teaser
Roche has received regulatory approval from the EMEA for erlotinib (Tarceva) for the treatment of patients with metastatic pancreatic cancer, in combination with gemcitabine.
Approval was based on data from the PA3 phase III study, which showed that for patients with metastatic disease, treatment with erlotinib plus gemcitabine results in a statistically significant survival compared with gemcitabine alone.
